Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4416340 | 0.80 | PLA2G7 (0.39) | MEN1USP2MAPTKMT2AKDM4E | |
| SCHEMBL4416381 | 0.80 | GAA (0.39) | MEN1USP2MAPTKMT2AKDM4E | |
| SCHEMBL4414439 | 0.68 | POLB (0.37) | MEN1USP2KMT2APOLB | |
| SCHEMBL4416313 | 0.68 | CYP19A1 (0.37) | MAPTKMT2A | |
| SCHEMBL9057541 | 0.66 | MAOB (0.44) | MEN1MAPTKMT2AKDM4EHTT | |
| SCHEMBL4573094 | 0.64 | CYP3A4 (0.48) | USP2MAPTKDM4EPOLBHTT | |
| SCHEMBL4551899 | 0.64 | ADORA2B (0.58) | — | |
| SCHEMBL13092524 | 0.63 | GFER (0.52) | MEN1MAPTKMT2AHTT | |
| SCHEMBL1333226 | 0.63 | ADORA2B (0.42) | KMT2A | |
| SCHEMBL9479523 | 0.59 | MAPT (0.39) | MEN1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161629-A1 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161629-A1 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA2A, ADORA3 | MEN1 1714/4885USP2 4422/4885MAPT 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.